Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
about
Vigabatrin for refractory partial epilepsyVigabatrin for refractory partial epilepsyVigabatrin and psychosisVigabatrin in the treatment of epilepsy: a long-term follow-up study.Effects of vigabatrin on partial seizures and cognitive function.Vigabatrin: a novel therapy for seizure disorders.Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor.Non-vision adverse events with vigabatrin therapy.Effects of vigabatrin on evoked potentials in epileptic patients.The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patientsInhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug.Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy.Vigabatrin: rational treatment for chronic epilepsy.(+/-)-(1S,2R,5S)-5-Amino-2-fluorocyclohex-3-enecarboxylic acid. A potent GABA aminotransferase inactivator that irreversibly inhibits via an elimination-aromatization pathwayContrast sensitivity is reduced in children with infantile spasms.Treatment of refractory complex partial seizures: role of vigabatrin.Mechanism of action of vigabatrin: correcting misperceptions.Vigabatrin therapy for refractory complex partial seizures: review of major European trials.Balancing clinical benefits of vigabatrin with its associated risk of vision loss.Response to vigabatrin in relation to seizure type.Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy.Vigabatrin induced Cell loss in the Cerebellar Cortex of Albino Rats.A multicentre study of vigabatrin for drug-resistant epilepsy.Human brain GABA transaminase tissue distribution and molecular expression.Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.
P2860
Q24201569-1E8BA5C3-27BB-4B39-B84D-3DA0A4725F7DQ24242702-FFAFEE91-0ECF-483B-9E2D-5CE7E5EA114BQ24562060-D2C36E6B-0870-41BD-A566-F0237D00D80EQ33629137-9D4A4223-4161-48DD-8C06-4AE6E2B57E4FQ33733068-73BF5482-7E42-4222-A6D9-B3EE42B36844Q33814543-C39843CD-DDE2-4FCD-8F23-F865D547C72AQ34038018-FF652491-D9C7-4AB7-8B41-3871C9B033DAQ34068916-A9A6648E-E964-4E6C-835C-842690633B9FQ34396870-0B216C5B-FCEB-4E92-80C6-AD9D0DA66BFCQ34396886-38BFEA3C-6C10-4F1E-B867-67D03B3DED6CQ34417684-103B743C-F0B6-4706-AB48-FE3927778BC0Q36942147-3445067E-9978-4792-A1BD-AB3896F90D5DQ36942736-BFE9F5C1-C936-4C5A-A67F-52E5BF66DF6EQ36944154-CA003FED-25B4-4B59-8A59-23F89EB264C5Q37431702-145A5E0B-86FF-4C10-9A34-395E416FE79DQ37620193-3347035B-AFC2-45B5-A027-94B5F224F7B1Q37953574-6A8F12A5-A9C8-43FE-9337-821833986E47Q37953576-573D5763-F730-43B8-81B0-98A939E8DDDCQ37953583-951F77C5-413E-4C75-9289-4A8181DBAF2CQ38671464-B9AAB694-3C7A-4C7F-8984-6AF500783EE7Q39435601-3C0FF114-C8F4-446A-99F3-5A92F0F7011BQ40570310-1A079154-BBEB-404C-82FE-56B5438B2F2EQ41848537-75C36D5E-1C8B-4159-A813-614E8D1C852DQ41848872-856C6B59-EDB4-472D-9144-4A39EEAB8123Q42017013-BB64AC72-9FFF-403C-8087-6DAA92AE6836Q43506256-390EDC59-4DF3-4105-940F-B5993E19DCCFQ54232900-CEC4B4DD-7E7A-4E45-A321-028990BF86CE
P2860
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@en
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@nl
type
label
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@en
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@nl
prefLabel
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@en
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@nl
P2093
P2860
P1433
P1476
Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
@en
P2093
P2860
P304
P356
10.1111/J.1528-1157.1986.TB03600.X
P577
1986-11-01T00:00:00Z